Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Capital Expenditures (2016 - 2025)

iBio (IBIO) has disclosed Capital Expenditures for 14 consecutive years, with $516000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 51500.0% to $516000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $563000.0 through Dec 2025, up 166.82% year-over-year, with the annual reading at $16000.0 for FY2025, 92.38% down from the prior year.
  • Capital Expenditures for Q4 2025 was $516000.0 at iBio, up from $32000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $3.4 million in Q2 2022, with the low at -$201000.0 in Q1 2023.
  • Average Capital Expenditures over 5 years is $1.1 million, with a median of $580000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures crashed 131.21% in 2023, then skyrocketed 51500.0% in 2025.
  • Over 5 years, Capital Expenditures stood at $2.1 million in 2021, then soared by 38.49% to $3.0 million in 2022, then tumbled by 82.87% to $506000.0 in 2023, then tumbled by 99.8% to $1000.0 in 2024, then surged by 51500.0% to $516000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $516000.0, $32000.0, and $1000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.